thumb
July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
September 14, 2020

Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

After achieving carbon neutrality in 2014, Biogen further bolsters its action against climate change with the goal to become fossil fuel free by 2040 and initiates research collaborations with global leaders to help address the effects of fossil fuel-driven air pollution on health.

thumb
September 11, 2020

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY ® (diroximel fumarate) Real-world findings evaluate quality of life benefits associated with TYSABRI ® (natalizumab) when compared to Ocrevus ® (ocrelizumab ) Additional real-world findings

thumb
September 8, 2020

New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planning Real-world data from MS PATHS identifies clinically relevant benchmarks to predict employment status among people with multiple sclerosis (MS) Biogen is

thumb
September 2, 2020

Biogen to Participate in the Morgan Stanley Virtual Global Healthcare Conference

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley Virtual Global Healthcare Conference. The webcast will be live on Monday, September 14, at 10:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section

thumb
August 27, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020

Cambridge, Mass. – August 27, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 61 st Annual Meeting of the Japanese Society of Neurology.

thumb
August 7, 2020

FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review

Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, Aug.

thumb
August 6, 2020

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders Biogen to receive exclusive option rights to two programs for neurodegenerative diseases

thumb
July 24, 2020

Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced there will be multiple data presentations from its Alzheimer’s disease (AD) clinical development portfolio, a virtual satellite symposium and AD PACE poster presentations at the Alzheimer’s Association

thumb
July 21, 2020

Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer

CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell joins Biogen from IQVIA™ (NYSE: IQV), where he is Executive Vice

thumb
July 21, 2020

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

In the long-term follow-up study of Zolgensma ® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA 1,2,3 The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical